Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells Retraction in /10.3892/ol.2023.13938

Taglieri,Ludovica; De Iuliis,Francesca; Giuffrida,Anna; Giantulli,Sabrina; Silvestri,Ida; Scarpa,Susanna

doi:10.3892/ol.2017.6597

Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells

Retraction in: /10.3892/ol.2023.13938

Authors:
- Ludovica Taglieri
- Francesca De Iuliis
- Anna Giuffrida
- Sabrina Giantulli
- Ida Silvestri
- Susanna Scarpa
View Affiliations

Affiliations: Department of Experimental Medicine, Sapienza University, I‑00161 Rome, Italy, Department of Molecular Medicine, Sapienza University, I‑00161 Rome, Italy
Published online on: July 18, 2017 https://doi.org/10.3892/ol.2017.6597
Pages: 3832-3838

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Everolimus (RAD001) is an inhibitor of mammalian target of rapamycin used in combination with exemestane to treat hormone receptor‑positive advanced breast cancer. However, not all patients are equally sensitive to RAD001 and certain patients develop resistance. Therefore, the present study analyzed the mechanisms involved in the resistance of breast cancer cells to RAD001 in order to identify a potential tool to overcome it. The effects of RAD001 on the inhibition of cell viability, on the induction of apoptosis and autophagy and on the regulation of survivin, an anti‑apoptotic protein, were evaluated in two breast cancer cell lines: BT474 (luminal B) and MCF7 (luminal A). RAD001 was demonstrated to induce autophagy in the two cell lines at following a short period of treatment (4 h) and to induce apoptosis exclusively in BT474 cells following longer periods of treatment (48 h). RAD001 induced the downregulation of survivin in BT474 cells and its upregulation in MCF7 cells. Consequently, inhibiting survivin with YM155 resulted in the acquired resistance of MCF7 cells to RAD001 being reverted, restoring RAD001‑induced apoptosis. These data demonstrated that RAD001 exerted anti‑proliferative and pro‑apoptotic effects on breast cancer cells, but that these effects were repressed by the simultaneous up‑regulation of survivin. Finally, the results demonstrated that inhibiting the expression of survivin resulted in the restoration of the anti‑neoplastic activity of RAD001.

View Figures

View References

1	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumors. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
2	Hurviz SA and Pietras RJ: Rational management of endocrine resistance in breast cancer: A comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 113:2385–2397. 2008. View Article : Google Scholar : PubMed/NCBI
3	Sobral AF, Amaral C, Correia-da-Silva G and Teixeria N: Unravelling exemestane: From biology to clinical prospects. J Steroid Biochem Mol Biol. 163:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
4	Hunter AM, LaCasse EC and Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis. 12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI
5	Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C and Cohen PA: mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 99:1992–2003. 2008.PubMed/NCBI
6	Kajiwara M and Masuda S: Role of mTOR inhibitors in kidney disease. Int J Mol Sci. 17:E9752016. View Article : Google Scholar : PubMed/NCBI
7	Kirchner GI, Meier-Wiedenbach I and Manns MP: Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 43:83–95. 2004. View Article : Google Scholar : PubMed/NCBI
8	Granata S, Dalla Gassa A, Carraro A, Brunelli M, Stallone G, Lupo A and Zaza G: Sirolimus and Everolimus pathway: Reviewing candidate genes influencing their intracellular effects. Int J Mol Sci. 17:E7352016. View Article : Google Scholar : PubMed/NCBI
9	Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnat M, Pritchard KI, Lebrun F, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, et al: In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictor response. Breast Cancer Res Treat. 149:669–680. 2015. View Article : Google Scholar : PubMed/NCBI
11	De Iuliis F, Salerno G, Giuffrida A, Milana B, Taglieri L, Rubinacci G, Giantulli S, Terella F, Silvestri I and Scarpa S: Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation. Tumor Biol. 37:2603–2611. 2016. View Article : Google Scholar
12	De Iuliis F, Taglieri L, Salerno G, Giuffrida A, Milana B, Giantulli S, Carradori S, Silvestri I and Scarpa S: The kinesin Eg5 inhibitor k858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells. Invest New Drugs. 34:399–406. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zhang C, Cao X, Gei Y, Wang Y, Liu G, Cheng G and Liu Q: Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells. Oncol Lett. 10:1627–1631. 2015.PubMed/NCBI
14	Zhang S, Liu B, Fan Z, Wang D, Liu Y, Li J, Wang N, Liu Y and Zhang B: Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K⁺ channels. Mol Med Rep. 13:3415–3422. 2016.PubMed/NCBI
15	Li WL, Lee MR and Cho MY: The small molecule survivin inhibitor YM155 may be an effective treatment modality for colon cancer through increasing apoptosis. Biochem Biophys Res Commun. 471:309–314. 2016. View Article : Google Scholar : PubMed/NCBI
16	Saran U, Foti M and Dufour JF: Cellular and molecular effects of the mTOR inhibitor everolimus. Clin Sci (Lond). 129:895–914. 2015. View Article : Google Scholar : PubMed/NCBI
17	Tanida I: Autophagy basics. Microbiol Immunol. 55:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
18	Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C and Cheng AL: Vertical blockade of the IGFR-PI3 K/Akt/mTOR pathway for treatment of hepatocellular carcinoma: The role of survivin. Mol Cancer. 13:22014. View Article : Google Scholar : PubMed/NCBI
19	Pavlidou A, Kroupis C and Dimas K: Association of survivin splice variants with prognosis and treatment of breast cancer. World J Clin Oncol. 5:883–894. 2014. View Article : Google Scholar : PubMed/NCBI
20	Song J, Su H, Zhou YY and Guo LL: Prognostic value of survivin expression in breast cancer patients: A meta analysis. Tumor Biol. 34:2053–2062. 2013. View Article : Google Scholar
21	Kim KW, Mutter RW, Cao C, Albert JM, Freeman M, Hallahan DE and Lu B: Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem. 281:36883–36890. 2006. View Article : Google Scholar : PubMed/NCBI
22	Zarzynska JM: The importance of autophagy regulation in breast cancer development and treatment. Biomed Res Int. 2014:7103452014. View Article : Google Scholar : PubMed/NCBI
23	Zambrano J and Yeh ES: Autophagy and apoptotic crosstalk: Mechanism of therapeutic resistance in HER2-positive breast cancer. Breast Cancer (Auckl). 10:13–23. 2016.PubMed/NCBI
24	Hjelmeland A and Zhang J: Metabolic, autophagic, and mitophagic activities in cancer initiation and progression. Biomed J. 39:98–106. 2016. View Article : Google Scholar : PubMed/NCBI
25	Jung YY, Lee YK and Koo JS: The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer. Expert Opin Ther Targets. 20:167–178. 2016. View Article : Google Scholar : PubMed/NCBI
26	Rauch A, Henning D, Schäfer C, Wirth M, Marx C, Heinzel T, Schneider G and Kramer OH: Survivin and YM155: How faithful is the liaison? Biochim Biophys Acta. 1845:202–220. 2014.PubMed/NCBI
27	Clemens MR, Gladkov OA, Gartner E, Vladimirov V, Crown J, Steinberg J, Jie F and Keating A: Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 149:171–179. 2015. View Article : Google Scholar : PubMed/NCBI
28	Papadopoulos KP, Lopez-Jimenez J, Smith SE, Steinberg J, Keating A, Sasse C, Jie F and Thyss A: A multicenter phase II study of sepantronium bromide (YM155) puls rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 57:1848–1855. 2016. View Article : Google Scholar : PubMed/NCBI